RBC Capital Reiterates Sector Perform on Vertex Pharmaceuticals, Maintains $424 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated a Sector Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $424.
June 04, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital has reiterated a Sector Perform rating on Vertex Pharmaceuticals and maintained a price target of $424.
The reiteration of a Sector Perform rating and maintenance of the price target at $424 by RBC Capital suggests a neutral outlook for Vertex Pharmaceuticals. This indicates that the stock is expected to perform in line with the sector, and there are no significant changes in the analyst's view that would drive the stock price up or down in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100